Abstract
From January 1989 to September 1992, 5 patients (age 58–68 years) were treated with percutaneous Pasteur BCG for superficial transitional cell carcinoma of the upper urinary tract. In 4 cases BCG was prophylactic after endourological resection of the tumors. In one case of bilateral Tis of the upper urinary tract, BCG was administered for therapeutical purposes. Every patient received 375 mg Pasteur BCG in 250 ml saline, every 2 weeks for 6 consecutive weeks in 2 patients, 5 weeks in 1, and 4 in 2. No major complications were observed. After a median follow-up of 10.2 months, 4 patients are disease free, 1 patient underwent nephroureterectomy. Percutaneous BCG in upper tract superficial transitional cell cancer seems a feasible option in selected cases.
Get full access to this article
View all access options for this article.